Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Turnpiker Mar. 13 at 5:47 PM

$INKT $IBRX I don’t usually crosspost but we have a partner in INKT. They were present at Saudi-US forum. I think they’re playing a part in Leonardo. Don’t sleep on them. IBRX Leonardo/Ai PR due soon may reveal partnership. Or, the Saudi-US investment PR I’m expecting may outline their involvement. I started a position at INKT

1 · Reply

Joby099 Mar. 13 at 3:23 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Peak5306 Mar. 13 at 10:46 AM

$INKT WTF happened 😳

1 · Reply

Joby099 Mar. 13 at 8:39 AM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Harunkaraca Mar. 13 at 12:29 AM

$INKT wooow what a Shit show

0 · Reply

Joby099 Mar. 12 at 8:12 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Biotechguy21 Mar. 12 at 2:55 PM

$AGEN it’s almost pos time for one of the worst stocks out there. Just like $INKT 🤡🤡💩💩😂😂

0 · Reply

pAmdd Mar. 12 at 12:43 PM

$INKT 8 is a target here

0 · Reply

Joby099 Mar. 12 at 8:12 AM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Dancady1 Mar. 11 at 10:34 PM

$INKT cure cancer and reach 10 billion market cap …lol

0 · Reply

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Mar 10, 2026, 9:47 AM EDT - 3 days ago

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

Mar 10, 2026, 5:30 AM EDT - 4 days ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Feb 3, 2026, 9:30 PM EST - 5 weeks ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Jan 8, 2026, 12:00 PM EST - 2 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Nov 20, 2025, 11:42 AM EST - 4 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 12:11 PM EST - 4 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 4 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Sep 29, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 18, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Aug 14, 2025, 4:15 PM EDT - 7 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 8 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 8 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 8 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 9 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 10 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 10 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Turnpiker Mar. 13 at 5:47 PM

1 · Reply

Joby099 Mar. 13 at 3:23 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Peak5306 Mar. 13 at 10:46 AM

$INKT WTF happened 😳

1 · Reply

Joby099 Mar. 13 at 8:39 AM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Harunkaraca Mar. 13 at 12:29 AM

$INKT wooow what a Shit show

0 · Reply

Joby099 Mar. 12 at 8:12 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Biotechguy21 Mar. 12 at 2:55 PM

$AGEN it’s almost pos time for one of the worst stocks out there. Just like $INKT 🤡🤡💩💩😂😂

0 · Reply

pAmdd Mar. 12 at 12:43 PM

$INKT 8 is a target here

0 · Reply

Joby099 Mar. 12 at 8:12 AM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Dancady1 Mar. 11 at 10:34 PM

$INKT cure cancer and reach 10 billion market cap …lol

0 · Reply

Joby099 Mar. 11 at 7:58 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Brianrudi Mar. 11 at 7:05 PM

$INKT Hahahahahahahahahaha......Daddys home!!

0 · Reply

Harunkaraca Mar. 11 at 6:15 PM

$INKT

0 · Reply

Spartrap Mar. 11 at 3:33 PM

$INKT I reckon management has raised 8-10 mil at 50% premium yesterday and we are good till mid 27. Q4 ER soon, with likely some tasty aacr nuggets. Yum

1 · Reply

Spartrap Mar. 11 at 3:27 PM

$INKT amazing two days. I played those traders like a fiddle 🙂

0 · Reply

Joby099 Mar. 11 at 3:22 PM

$ATPC $INKT $VTAK $SGN $MRNO

0 · Reply

Donniechen12345 Mar. 11 at 2:23 PM

$INKT lol $8 soon

0 · Reply

pooch0 Mar. 11 at 2:13 PM

$INKT yikes

0 · Reply

pAmdd Mar. 11 at 2:01 PM

$INKT got stopped out

0 · Reply

Jacky2322 Mar. 11 at 1:58 PM

$INKT this was the time for it go back to 17 minimum but they robbing people as usual

0 · Reply

Jacky2322 Mar. 11 at 1:57 PM

$INKT back to where it was crazy it just shows these companies are just scammers even when u invest at the low price of 15 it still goes back down whyy even pn good news

0 · Reply

DEMIAN1 Mar. 11 at 1:43 PM

$INKT Eventually, the stock rises with tremendous news. The short sale must be closed quickly.

0 · Reply

Market Cap	48.26M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	112,500
Avg Vol	338,650
Day's Range	N/A - N/A
Shares Out	4.69M
Stochastic %K	3%
Beta	0.35
Analysts	Strong Sell
Price Target	$39.00